Clinical Trials Arena speaks to Lineage Cell Therapeutics CEO Brian Culley about the firms lead candidate OpRegen for dry AMD and the unexpected cases of retinal restoration in an ongoing Phase I/IIa trial.
Age-related macular degeneration (AMD) is one of the worlds leading causes of blindness in people over the age of 50. There are two types of the disease wet AMD and dry AMD.
The less common wet AMD is well understood as being caused by leaky blood vessels and has numerous effective treatments available. Dry AMD causes layers of the macula (including the photoreceptors and the retinal pigment epithelium) to get progressively thinner and function less and less well. This is called atrophy.
Advanced cases of dry AMD are known as geographic atrophy (GA) because large sections of the retina stop functioning.
There are around two million people in the US suffering with this severe form of the condition, and there are currently no treatments available, representing a huge unmet need. Historically, dry AMD has been viewed as an inevitably progressive disease.
California-headquartered Lineage Cell Therapeutics is taking a very different approach to the disease compared to traditional pharmaceutical approaches, which often involve targeting inflammation with small molecules and antibodies and treating patients either orally or locally in the eye.
With its lead candidate OpRegen, which is in an ongoing Phase I/IIa open-label clinical study, Lineage is manufacturing brand new retina cells and taking a transplant approach to the condition.
Its been very exciting what we have seen in the clinic so far, the companys CEO Brian Culley tells Clinical Trials Arena.
The one-time therapy consists of allogeneic retinal pigment epithelium (RPE) cells and is administered subretinally in patients with dry AMD and GA. The patient is locally anaesthetised and the procedure only takes about 30 minutes.
The firm uses pluripotent stem cells as a starting material to manufacture the therapy. Just as flour can become bread or a cookie, [pluripotent] stem cells have within them the capability or the capacity to become any of the 200 cell types in your body, says Culley.
We instruct the cells to become a specific and exclusive type of cell and then we transplant those into the body. In the case of dry AMD we manufacture enormous numbers of retina cells and only retina cells, and then we transplant those cells to treat disease of the eye.
The manufacture of cells requires exquisite control over your process as you are manufacturing a dynamic living entity at scale, Culley says. If you cannot manufacture at large scale, you will never have an economically affordable solution.
The allogeneic rather than autologous nature of Lineages manufactured retinal cells provides advantages in scale, he argues.
There are approaches that people take even in dry AMD where they take cells from a persons eye, and they manipulate them and then they replace them, but here youre talking about personalised medicine, which sounds great until you consider the cost.
Weve invested significantly in our manufacturing skills and created a huge number of patents from our manufacturing techniques. We are already at the point where, in a three-litre bioreactor, we can manufacture the equivalent of 2500 clinical courses so many thousands of treatments can come from basically a milk jug and scaling up is straightforward because we grow the cells on little microcarriers. We grow the cells in three-dimensional space and that allows us to increase the volume because the cell doesnt really know the difference between growing in a tiny thimble or growing in a swimming pool.
Cell therapy brings with it the complexity of dealing with a whole cell rather than just a single molecule, but that complexity is also the key to this approach.
By the time retina cells are dying off, there are so many things going wrong in the eye that we dont think that a single molecule is going to have enough horsepower to be able to drive a clinical outcome, Culley says. So we think you have to replace the entire cell.
The ongoing Phase I/IIa clinical trial evaluating OpRegen enrolled 24 people. Twelve of the participants treated with the therapy had very advanced AMD and were legally blind.
Culley says this cohort was used to assess the treatments safety and not much was seen in terms of efficacy but some encouraging anatomical changes were observed.
In the eye, the vision cycles metabolic activity leads to a waste material called drusen, which is cleared by healthy retina cells. In some of these patients, a reduction in drusen was observed.
The next group of 12 patients disease was far less advanced and they had far better baseline vision than the first; some even still had their drivers licenses. At their earlier stage of disease, they had more retinal tissue with potential to be rescuable. When the trial moved into the group of patients with better starting vision, Culley and his team started to see very exciting effects in terms of visual acuity and anatomical changes.
We were really happy to see that in that group of individuals, weve had better results, Culley says. We have seen an increase in vision, so people are seeing more letters on an eye chart, compared to their untreated eye. The majority of untreated eyes have gotten worse, which is what you would expect over time. In the treated eye it is reversed; weve actually seen people gain vision.
No patients in the trial, which started treating patients with OpRegen five years ago, have rejected the cells, meaning all have stably integrated them. Most exciting of all are three cases of retinal restoration, which Culley says is really unprecedented stuff due to the progressive nature of the disease.
This is a new phenomenon, says Culley. Human beings cannot regenerate retinal tissue; when you lose retina cells, theyre gone forever. And thats what this disease is all about losing retina cells.
Over a year ago, while looking at images of a patients eyes after OpRegen treatment, doctors noticed retina cells growing back around the spot of GA.
We were absolutely blown away, Culley says. We actually sat on this initial finding for quite some time, because even though it was incredible, and exciting and maybe even predictable in some ways youre transplanting cells and if theyre taken up, survive and are functional why wouldnt this happen but nobody thought it was possible.
The question the firm focused on while analysing the data and sending it out to third-party independent retinal imaging experts was simple why did this patient experience retinal tissue regeneration while no one else did?
We think the answer was that patient got a very complete delivery of our cells all across that atrophic area, explains Culley.
Lineage repeated the procedure and got similarly extensive coverage across another two patients, and they also exhibited retinal restoration. So we now have three cases that have exhibited retinal restoration. Now its not a one-time thing we have some understanding, we could reproduce it, its quite clear.
One of the trial participants atrophy originally got smaller but now has grown back to the size it was three years ago meaning that essentially her AMD had been halted.
In the three years since I had the operation, the eye that was operated on has not deteriorated which I reckon is almost miraculous, said the patient, Sonia Cohen. Its really amazing. I cant imagine what my life would have been like if I had continued to deteriorate.
Culley says that with OpRegens clinical research thus far, his team has learned that being more aggressive with where they place the cells leads to better outcomes.
Now we know that so we can repeat that. I think over time, it will get better and better, and Id be really delighted if we get up to the point where it becomes like LASIK surgery, which is close to 100% success rate.
Later this year, Lineage is planning to discuss the design of its next trial with the US Food and Drug Administration. For now, the three cases of retinal restoration or reversal of AMD have provided a vital proof of concept.
We want to go as quickly as possible into the next study, and having the backing of this reversal is very exciting because, from a statistical perspective, we probably dont need 2,000 patients were talking about hundreds of patients.
On the future of cell therapy, Culley says it is a field that is quickly maturing. It used to be like the wild west but now companies like ours are doing these rigorous clinical trials to find out ways to control it and dry AMD is a really cool place to start, he says. But, there are 199 other cell types that we could investigate so there is a long-term medical story here that is really about ushering in a new branch of medicine manufacturing cells, transplanting them that Im really excited to be part of.
Dry AMD is not the firms only focus; it has also embarked on clinical trials for VAC2, an allogeneic dendritic cell therapy currently enrolling a Phase I trial for the treatment of non-small cell lung cancer and has treated 25 people with spinal cord injuries with its candidate OPC1 in a Phase I/II trial, which Culley says has been very emotional.
I know if I live long enough my retina cells are going to die off; if I smoke four packs of cigarettes [a day] I will get lung cancer, but nobody expects to get a spinal cord injury. All of these young people who fall off mountain bikes or get in car crashes and their lives are turned upside down. Their ability to just get some hand control to be able to move their wheelchair thats mobility and independence so if we can help regain mobility, thats freedom so I think the spinal cord program is really powerful.
Electronic Data Capture Solutions for Clinical Trials
Bespoke, Cost-Effective Preclinical Cancer Model Searches for Preclinical Studies
Drug Processing Technology and Laboratory Equipment
Electronic Data Capture Solutions for Clinical Trials
28 Aug 2020
Bespoke, Cost-Effective Preclinical Cancer Model Searches for Preclinical Studies
28 Aug 2020
Drug Processing Technology and Laboratory Equipment
28 Aug 2020
Go here to read the rest:
OpRegen: tackling the leading cause of blindness with cell replacement - Clinical Trials Arena
- Cell Therapy Basics - February 21st, 2024
- FDA Approves Amtagvi, First Cell Therapy for Skin Cancer - BioPharm International - February 21st, 2024
- Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial - PR Newswire - February 21st, 2024
- Astellas and Kelonia enter CAR-T cell therapy collaboration worth over $800m - PMLiVE - February 21st, 2024
- Bridging Therapy With CAR T-Cell Therapy in LBCL - OncLive - February 21st, 2024
- FDA approves first cell therapy to treat aggressive forms of melanoma - NPR - February 21st, 2024
- Iovance, with approval of 'TIL' cell therapy, readies for complex launch - Yahoo Finance - February 21st, 2024
- Cancer treatment: FDA approves type of cell therapy for patients with late-stage melanoma - FOX 26 Houston - February 21st, 2024
- Pharmalittle: We're reading about weight loss drugs, a cell therapy for melanoma, and more - STAT - February 21st, 2024
- On heels of cancer cell therapy win, Peninsula biotech looks to raise $211M - San Francisco Business Times - The Business Journals - February 21st, 2024
- FDA approves cell therapy to treat melanoma - FOX 26 Houston - February 21st, 2024
- Toddler Beats Childhood Leukemia After Car T-Cell Therapy - City of Hope - February 21st, 2024
- FDA Approves First One-time Cell Therapy for a Solid Tumor - BioSpace - February 21st, 2024
- Iovance wins FDA approval for cell therapy - BioProcess Insider - BioProcess Insider - February 21st, 2024
- FDA Approves Iovance Cancer Treatment, the First Cell Therapy for a Solid Tumor - MedCity News - February 21st, 2024
- Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas - Medical Xpress - February 21st, 2024
- Reinforcing Cell Therapy with Microfluidic Cell Sorting - RegMedNet - February 21st, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 21st, 2024
- Understanding CAR T-Cell Therapy: Balancing the Risks and Benefits - Medriva - February 21st, 2024
- Keeping Track: Iovance's Amtaqvi Approval Brings T Cell Therapy To Solid Tumors - Pink Sheet - February 21st, 2024
- Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be ... - Yahoo Finance - February 21st, 2024
- What is CAR-T cell therapy, used for cancer treatment? Experts explain - India Today - India Today - February 21st, 2024
- UPDATE: 2seventy splits once more, sending cell therapy pipeline to Regeneron in 'dramatic' change - FierceBiotech - January 31st, 2024
- Revolutionary CAR T-cell therapy shows promise in reversing age-related metabolic dysfunction - News-Medical.Net - January 31st, 2024
- BioCardia Pivots to Biomarker Strategy to Prove Heart Failure Cell Therapy Benefits - precisionmedicineonline.com - January 31st, 2024
- Sequencing With CAR T-Cell Therapy for LBCL - OncLive - January 31st, 2024
- Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy ... - pnas.org - January 31st, 2024
- Regeneron to acquire 2seventy's cell therapy pipeline - Yahoo Finance - January 31st, 2024
- Trial of cell-based therapy CK08031 finishes dosing 1st patients - ALS News Today - January 31st, 2024
- Exploring Gene and Cell Therapy Integration in Pharmacies - PharmaNewsIntel - January 31st, 2024
- HBS Alumna Fighting Cancer with a Novel Cell Therapy - MBA - hbs.edu - January 31st, 2024
- YUHS partners with KURE.AI Therapeutics for cell therapy development - KBR - January 31st, 2024
- Global CAR-T Cell Therapy Market Report 2024-2034: Accelerated Growth Fueled by Intensive R&D, Growing Medical ... - Yahoo Finance - January 31st, 2024
- Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy ... - PR Newswire - January 31st, 2024
- A new chapter in cell therapy: engineered B cells reach the clinic for the first time - Labiotech.eu - January 31st, 2024
- Harnessing the Dark Genome: New Approach Greatly Improves Cancer T-Cell Therapy - SciTechDaily - January 31st, 2024
- Cell therapies | Harvard Stem Cell Institute (HSCI) - November 16th, 2023
- Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological... - April 15th, 2023
- Basal Cell Carcinoma Treatment - The Skin Cancer Foundation - January 4th, 2023
- Adoptive Cell Therapy - Cancer Research Institute (CRI) - December 27th, 2022
- National Medical Commission prohibits use of stem cell therapy to treat patients with autism - Hindustan Times - December 18th, 2022
- Tumor buster - where will the CAR-T cell therapy missile go? - December 18th, 2022
- Gilead lands new cell therapy for Kite in $225M Arcellx deal, providing global scale for future J&J-Legend showdown - FierceBiotech - December 10th, 2022
- Non-Small Cell Lung Cancer Treatment (PDQ)Patient Version - November 24th, 2022
- CAR-T Cell Therapy Program - Frequently asked questions - November 24th, 2022
- EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell... - November 24th, 2022
- Radiation Therapy for Non-Small Cell Lung Cancer - November 6th, 2022
- AvenCell to Present New Data from Lead Universal CAR T Cell Therapy Program at 64th American Society of Hematology Annual Meeting and Exposition -... - November 6th, 2022
- Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials - MarketWatch - November 6th, 2022
- Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the... - November 6th, 2022
- Photodynamic Therapy to Treat Cancer - NCI - October 29th, 2022
- Researchers at University Hospitals create a breakthrough in CAR-T cell therapy for cancer patients - News 5 Cleveland WEWS - October 29th, 2022
- Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th... - October 29th, 2022
- Gilead, working to improve cancer cell therapy, partners with California startup - BioPharma Dive - October 21st, 2022
- Allogene starts first pivotal trials of an 'off-the-shelf' cell therapy for cancer - BioPharma Dive - October 13th, 2022
- Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers - Business Wire - October 13th, 2022
- CAR T-cell Therapy Market Riding on the Wave of Growth and will Grow at a CAGR of 30.6% to 2031 | TMR Study - GlobeNewswire - October 13th, 2022
- Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors - PR Newswire - October 13th, 2022
- Cell Therapy Technologies Market Expected to Reach US ~$12.27 Billion and CAGR 14.5% by 2030 Polaris Market Research - Digital Journal - October 13th, 2022
- Early Data on GPRC5D-Directed CAR T-Cell Therapy Open Doors for New Myeloma Treatment Strategies - Precision Oncology News - October 13th, 2022
- BREAKTHROUGH TECHNOLOGY FOR IPS-DERIVED CELL THERAPIES TURNED INTO GMP PLATFORM BY TREEFROG THERAPEUTICS & INVETECH - PR Newswire - October 13th, 2022
- Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases -... - October 13th, 2022
- Breast cancer treatment: These targeted therapies are a ray of hope for patients - Health shots - October 13th, 2022
- Two-Year Clinical Data for DiscGenics's Progenitor Cell Therapy for Lumbar Disc Degeneration to Be Presented at NASS 2022 - PR Newswire - October 13th, 2022
- Mayo Clinic Minute: What is CAR-T cell therapy? - Finger Lakes Times - October 13th, 2022
- Gamma Biosciences and Lonza Collaborate to Co-develop Reagents for Clinical Cell Selection in the Cocoon Platform USA - English - USA - English - PR... - October 13th, 2022
- Merck and Moderna Move Forward with Personalized Cancer Vaccine - BioSpace - October 13th, 2022
- First Patient With B-NHL or CLL Treated With MB-106 in Phase 1/2 Study - Targeted Oncology - October 13th, 2022
- MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022 - Yahoo Finance - October 13th, 2022
- Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy - GlobeNewswire - October 13th, 2022
- Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy -... - October 13th, 2022
- Integrating CAR T-Cell Therapy Into Community Oncology Practices - Targeted Oncology - October 4th, 2022
- About CAR-T cell therapy - Mayo Clinic - October 4th, 2022
- Autologous immune-cell therapy, practiced in Japan, now helping Vinmec Hospital, treat cancer patients in Hanoi, Vietnam, after technology transfer by... - October 4th, 2022
- Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B... - October 4th, 2022
- Regenerative Spine and Pain Institute: Treating Pain with PRP and Stem Cell Therapy - Community News - October 4th, 2022
- City of Hope To Accelerate Immunotherapy Research And Treatment Innovation with $15 Million Gift From Ted Schwartz Family - City of Hope - October 4th, 2022
- Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel - Business Wire - October 4th, 2022
- Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors - Yahoo Finance - October 4th, 2022
- SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ AAC Platform's Potential as an Effective Red Blood Cell-Derived Immunotherapy -... - October 4th, 2022